Treatment of ithy, red, dry and cracked skin condition (Eczema) by of Unani drug

A Clinical Study to Evaluate the Efficacy and Safety of Marham-e-Safeda Kafoori in the Management of Nar Farsi (Eczema)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/12/010957

Enrollment

Registered

2017-12-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Nar Farsi (Eczema)

Interventions

Intervention1: Study Drug: Marham-e-Safeda Kafoori: Topical application on affected parts. Control Intervention1: Control Group : Clobetasol propionate: Dosage form: Ointment Route of Adminstration:

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of any sex in the age group of 18 to 65 years 2. Patients having the following symptoms: 3. Erythema 4. Scaling 5. Lichenification 6. Excoriation Hyperpigmentation Burnig Sensation Itching

Exclusion criteria

Exclusion criteria: 1. Patients aged below 18 years and above 65 years 2. Patients on concomitant therapy 3. Co-morbid patient 4. Patients suffering from: Diabetes mellitus, Hypertension 5. Pregnant and Lactating women

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy of Marham-e-Safeda Kafoori in the management of Nar Farsi Talluqi (Contact Eczema) To evaluate safety of Marham-e-Safeda Kafoori in the management of Nar Farsi Talluqi (Contact Eczema)Timepoint: at baseline, 7th, 14th, 21st, 28th, 35th and 42th day	—

Secondary

Measure	Time frame
Assessment of safety of the study drugTimepoint: at baseline, 7th, 14th, 21st, 28th, 35th and 42th day	—

Countries

India

Contacts

Public ContactProf Qamar Uddin

Central Research Institute of Unani Medicine, Hyderabad

ccrumnawab@gmail.com8100992044

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026